SEC Form 4 · accession 0000950142-17-000569

CDK Global, Inc. · CDK

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President, CDK North America

Period of report

Mar 8, 2017

Accepted (ET)

Mar 10, 2017 · 7:01 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001609702

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 8, 2017	M	9,650	$17.96	A	70,799	D
Common Stock	Mar 8, 2017	M	14,476	$20.244	A	85,275	D
Common Stock	Mar 8, 2017	M	22,059	$21.72	A	107,334	D
Common Stock^F1	Mar 8, 2017	S	46,185	$66.474	D	61,149	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (Right to Buy)^F2	$17.96	Mar 8, 2017	M	9,650	D	—	Feb 7, 2021	Common Stock	9,650	D
Stock Option (Right to Buy)^F2	$20.244	Mar 8, 2017	M	14,476	D	—	Jan 25, 2022	Common Stock	14,476	D
Stock Option (Right to Buy)^F2	$21.72	Mar 8, 2017	M	22,059	D	—	Jan 24, 2023	Common Stock	22,059	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple open market transactions at prices ranging from $66.30 to $66.60, inclusive. The report person undertakes to provide to CDK Global, Inc., a security holder thereof, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1).
F2Grant has a graded vesting schedule. Date Exercisable varied for each vesting tranche.